Abstract: The present disclosure relates to novel silenced antibody-based therapeutic agent for the treatment of tumors and/or metastasis. The therapeutic agents of the present disclosure are monovalent and are specific for MET.
| # | Name | Date |
|---|---|---|
| 1 | 202517105446-STATEMENT OF UNDERTAKING (FORM 3) [31-10-2025(online)].pdf | 2025-10-31 |
| 3 | 202517105446-Sequence Listing in PDF [31-10-2025(online)].pdf | 2025-10-31 |
| 4 | 202517105446-REQUEST FOR EXAMINATION (FORM-18) [31-10-2025(online)].pdf | 2025-10-31 |
| 5 | 202517105446-PRIORITY DOCUMENTS [31-10-2025(online)].pdf | 2025-10-31 |
| 6 | 202517105446-POWER OF AUTHORITY [31-10-2025(online)].pdf | 2025-10-31 |
| 7 | 202517105446-NOTIFICATION OF INT. APPLN. NO. & FILING DATE (PCT-RO-105-PCT Pamphlet) [31-10-2025(online)].pdf | 2025-10-31 |
| 8 | 202517105446-FORM 18 [31-10-2025(online)].pdf | 2025-10-31 |
| 9 | 202517105446-FORM 1 [31-10-2025(online)].pdf | 2025-10-31 |
| 10 | 202517105446-DRAWINGS [31-10-2025(online)].pdf | 2025-10-31 |
| 11 | 202517105446-DECLARATION OF INVENTORSHIP (FORM 5) [31-10-2025(online)].pdf | 2025-10-31 |
| 12 | 202517105446-COMPLETE SPECIFICATION [31-10-2025(online)].pdf | 2025-10-31 |
| 13 | 202517105446-Proof of Right [06-01-2026(online)].pdf | 2026-01-06 |